idecabtagene vicleucel
2seventy bio,bms
#ims2022 good reminder by dr. hansen of of how different soc populations are from clinical trials when it comes to car-t. adds to work by showing how few pts are currently eligible even for soc label: 
Asst Professor @UWMedicine @fredhutch, s/p @UCSFCancer heme/onc ?? CAR-T training. #MMsm #TcellRx #cellphonesandcelltherapies ????

COI: https://t.co/3Uuojuio6R